Coya Therapeutics shares rise 1.61% intraday after FDA IND clearance for ALS trial and strategic partnerships.

Wednesday, Sep 3, 2025 2:46 pm ET1min read
COYA--
Coya Therapeutics, Inc. rose 1.61% in intraday trading, with the company's CEO, Arun Swaminathan, discussing recent progress and strategic vision in an exclusive Q&A with PRISM MarketView. The interview highlighted FDA acceptance of the Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS), enabling the initiation of a Phase 2 clinical trial, and strategic partnerships, including with Dr. Reddy’s Laboratories, which provide financial support.

Coya Therapeutics shares rise 1.61% intraday after FDA IND clearance for ALS trial and strategic partnerships.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet